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 1 
Abstract 2 
Objective 3 
To describe the incidence, outcome and identify possible risk factors for Post Attenuation 4 
Neurological Signs (PANS) and seizures in dogs that have undergone attenuation of a 5 
single congenital portosystemic shunt (CPSS). 6 
Study Design 7 
Retrospective cohort study.  8 
Sample Population 9 
Dogs (n=253) with a single, congenital portosystemic shunt.  10 
Methods 11 
Medical records of dogs with a single CPSS surgically attenuated between February 2000 12 
and July 2015 were reviewed for signalment, pre and post-operative clinical data, 13 
including the occurrence of PANS. Univariable and multivariable binary logistic 14 
regression was used to assess risk factors for PANS and for seizures.  15 
Results  16 
Twenty eight (11.1%) dogs developed PANS, including twelve (4.7%) dogs that 17 
seizured. Five (17.9%) dogs with PANS did not survive to discharge.  18 
The risk factors for PANS included the presence of HE immediately pre-operatively  19 
(p=0.038, odds ratio 2.704, confidence interval 1.057-6.922) and increasing age 20 
(p<0.001, odds ratio 1.476, confidence interval 1.223-1.780). The risk factors for seizures 21 
included the presence of HE immediately pre-operatively (p=0.048, odds ratio 3.538, 22 
confidence interval 1.013-12.363) and increasing age (p=0.009, odds ratio 1.364, 23 
confidence interval 1.082-1.720).  24 
 25 
Conclusions 26 
Pre-operative HE and older age in dogs with a CPSS increase the odds of developing 27 
PANS and seizures. Neither extrahepatic or intrahepatic shunts were at an increased risk 28 
of developing PANS or seizures. Prophylactic levitiracetam was not protective for the 29 
development of PANS or seizures.  30 
 31 
Clinical Significance 32 
Our findings would suggest that surgical attenuation of a single CPSS should not be 33 
excessively delayed and that clinical signs of HE should be stabilized before surgery.  34 
Introduction 35 
Post Attenuation Neurological Signs (PANS) are a complication of the surgical 36 
management of Congenital Portosystemic Shunts (CPSS) reported in up to 12% of 37 
dogs.1–7 Signs vary from mild ataxia 2,8 to generalized seizure activity. 5,6,9 PANS is a 38 
well recognised complication in dogs, however, the underlying aetiology is unclear and 39 
may be linked to changes associated with hepatic encephalopathy (HE) prior to surgery. 40 
6,9  41 
 42 
Dogs with CPSS often show signs of HE, a poorly understood syndrome of neurological 43 
signs caused by alterations of multiple factors including ammonia and false 44 
neurotransmitters.10–12 In dogs with CPSS, ammonia and inflammatory mediators predict 45 
the presence of HE13 and indicators of inflammation reduce following successful CPSS 46 
attenuation.14 HE is commonly observed in people secondary to a variety of liver 47 
diseases, however the pathogenesis remains unclear.  48 
 49 
HE may cause chronic alterations in the central nervous system15–19 and there is direct 50 
evidence of astrocyte alterations in the brains of dogs with CPSS. 10,21 It is hypothesised 51 
that the central nervous system becomes adapted to an abnormal metabolic environment 52 
pre-operatively and a sudden change to this favours an excitatory state.2 Alternatively, 53 
damage to the CNS as a result of chronic portosystemic shunting, coupled with a 54 
metabolic event post attenuation could result in PANS.6  55 
 56 
PANS is recognised to be a separate entity to HE,1 occurring even when the CPSS is fully 57 
attenuated at surgery.22,23 In one study all animals affected with PANS had normal levels 58 
of ammonia,24 whereas HE is commonly associated with hyperammonaemia.13  59 
 60 
Increasing age has been associated with PANS in some studies 2,6,9, but not others.25,26 61 
There is conflicting evidence about whether dogs with extrahepatic shunts carry an 62 
increased risk of developing PANS, and the effect of the method or degree of shunt 63 
attenuation is unknown.2,4,23,25,27  64 
 65 
Changes in sodium affect osmolality. Central pontine myelinolysis is one of the most 66 
severe causes of post-operative neurological signs in people undergoing orthotopic liver 67 
transplantation and is associated with rapid correction of hyponatraemia.28 In addition a 68 
reduction of osmolality is associated with increased risk of seizures in people and other 69 
animals.19,29  70 
 71 
Administration of prophylactic anti-seizure medication to dogs with CPSS in the peri-72 
operative period has shown mixed results. Peri-operative levetiracetam seemed to reduce 73 
the incidence of post-operative seizures in one retrospective study,3 whereas 74 
phenobarbitone potentially reduced the severity, but not the incidence of neurological 75 
dysfunction in another.276 
77 
78 
The aim of the current study was to retrospectively review the records of dogs that had 79 
undergone surgical attenuation of a single CPSS, to describe the incidence, outcome and 80 
identify risk factors for PANS and seizures. We hypothesised that age, the presence of 81 
HE pre-surgery, extrahepatic shunt morphology and alterations in osmolality post-82 
operatively would be significantly associated with the incidence of PANS and seizures. 83 
Additionally, we hypothesised that peri-operative administration of levetiracetam would 84 
not affect the incidence of PANS or seizures.  85 
Materials and Methods 86 
The records of dogs that underwent surgery for the attenuation of a single congenital 87 
portosystemic shunt at our institution between February 2000 and July 2015 were 88 
reviewed. Diagnosis of a single CPSS was confirmed at surgery with a mesenteric 89 
portovenogram in all cases.30 The details recorded were signalment, bodyweight,  90 
duration of clinical signs related to a CPSS, (neurological, urinary and gastrointestinal), 91 
severity and duration of HE prior to surgery, response to medical treatment prior to 92 
surgery, pre-surgery serum albumin, pre and 24hr post-operative plasma ammonia,  peri-93 
operative levetiracetam, shunt type (intrahepatic or extrahepatic), method of attenuation 94 
and the degree of attenuation achieved, post-operative serum osmolality at three time 95 
points, the nature, timing and outcome of any complications related to PANS and the 96 
number of days hospitalisation. Ammonia was measured using a Stasar III 97 
Spectrophotometer (Gilford Instrument Laboratories Incorporated, Ohio, USA) or a 98 
Jenway 6310 Spectrophotometer (Bibby Scientific Limited, Staffordshire, UK). Albumin 99 
was measured using a ILab 600 clinical chemistry analyser (Instrumentation Labaratory, 100 
Werfen, Warrington, UK). 101 
 102 
Electrolytes, urea (BUN) and glucose were measured using a blood gas analyser.  103 
Osmolality was calculated by the blood gas analyser using the following formula: 104 
Osm(mOsm/kg) = 1.86[Na+] + ([Glu]/18) + ([BUN]/2.8) + 9. The same blood gas, 105 
electrolyte and metabolite analyser was used for individual dogs, but three analysers were 106 
used over the study period (<2003 IRMA TRUpointR, LifeHealth UK; 2003-2011 Stat 107 
ProfileR Critical Care Xpress, Nova Biomedical UK; >2011 Stat ProfileR pHOxR Ultra, 108 
Nova Biomedical UK).  109 
HE before the commencement of medical management (Table 1) and immediately pre-110 
operatively (Table 2) was graded. Dogs were deemed to have PANS if any neurological 111 
signs were noted after surgery and before discharge. PANS were graded as mild, 112 
moderate or severe (Table 3). Dogs underwent CPSS attenuation according to a 113 
standardized surgical protocol.25,30 The anaesthesia protocol was at the discretion of the 114 
anaesthetist. As previously reported, the decision to partially or completely attenuate the 115 
CPSS was made on the basis of portal pressure measured via mesenteric vein 116 
catheterization and visual assessment of the pancreas and intestinal tract for signs of 117 
portal hypertension. Dogs that could tolerate a complete attenuation were treated with a 118 
complete acute suture ligation, those that could not were treated either with a partial 119 
suture ligation or a cellophane band.30 120 
 121 
Statistical analysis was performed using the statistical software package IBM SPSS 122 
Statistics 23.0.0 (SPSS (UK) Limited IBM, Woking, UK).  Data were assessed 123 
graphically for normality. Median and range are reported for non-normally distributed 124 
variables. Categorical data are reported as percentages. The pre-operative and post-125 
operative levels of plasma ammonia were compared using the Wilcoxon Signed Rank 126 
Test. Statistical significance was set P ≤ 0.05. 127 
 128 
Univariable binary logistic regression was performed using each potential predictor 129 
variable (Tables 5 and 6) as an initial screening to identify possible risk factors for PANS 130 
and seizures for use in multivariable models.  131 
 132 
Variables were selected for univariable binary logistic regression that had been 133 
previously associated with outcome or were related to the study hypothesis.2,3,6,13,19,31 134 
Multivariable binary logistic regression models were then developed initially using the 135 
variables with a P ≤ 0.10 in the univariable analysis. Variables were sequentially entered 136 
into the logistic regression model and retained if P ≤ 0.05. Once the model was finalized, 137 
excluded variables were re-assessed by individually re-entering them back into the 138 
model. Two models were created, one for PANS and one for seizures. 139 
 140 
Correlation between variables used in the multivariable analysis was assessed using a 141 
Spearman’s Rank Correlation.  142 
  143 
Results 144 
Two hundred and fifty-three dogs with a single CPSS were included in the study. Three 145 
other cases were omitted due to incomplete medical records. Where dogs had more than 146 
one surgery only the details of the first surgery were included. One hundred and thirty-147 
seven dogs (54.2%) were male and 116 dogs (45.8%) were female. One hundred and 148 
seventy-five dogs (69.2%) were intact and 78 dogs (30.8%) were neutered. The median 149 
age at time of surgery was 0.87 years (range 0.20-11.98). The median weight at surgery 150 
was 6.3kg (range 1.0-50.0). 151 
 152 
The median duration of clinical signs prior to surgery was 57 days (range 5-1436). HE 153 
grade prior to medical management was 1 in 71 dogs (28.1%), 2 in 108 dogs (42.7%), 3 154 
in 72 dogs (28.5%) and 4 in two dogs (0.8%). Two hundred and thirty-eight dogs (94.1%) 155 
were treated with medical management prior to surgery and 15 dogs (5.9%) did not 156 
receive any treatment. Of the 238 dogs that had medical management prior to surgery 157 
there was a good response in 176 dogs (73.9%), a moderate response in 49 dogs (20.6%) 158 
and a poor response in 13 (5.5%). The HE grade following medical management was 159 
grade 1 in 196 dogs (82.4%), grade 2 in 37 dogs (15.5%), grade 3 in four dogs (1.7%) 160 
and grade 4 in one dog (0.4%). The median duration of medical management prior to 161 
surgery was 23 days (range 0-730). 162 
 163 
One hundred and ninety-six dogs (77.5%) had an extrahepatic CPSS and 57 dogs (22.5%) 164 
had an intrahepatic CPSS. One hundred and forty-eight dogs (58.5%) were able to 165 
tolerate a partial attenuation and 105 dogs (41.5%) were able to tolerate a complete 166 
attenuation. Of the 148 dogs treated with a partial attenuation 12 (8.1%) were treated with 167 
a cellophane band, the remainder with partial suture ligation. 168 
 169 
Fifty-four dogs (21.3%) received peri-operative levetiracetam 20mg/kg orally every 8 170 
hours for a minimum of 24 hours pre-operatively and a minimum of five days post-171 
operatively. Dogs may have received levetiracetam for longer if prescribed by the 172 
referring veterinary surgeon.  173 
 174 
Serum albumin was measured pre-operatively in 227 dogs (89.7%). The median albumin 175 
was 26.2g/l (range 7.9-35.8g/l), the reference range 49-71g/l. 176 
 177 
Plasma ammonia was measured in 186 dogs (73.5%) pre-operatively. The median 178 
ammonia concentration was 163.0μmol/l (range 8-590), reference range 0-70μmol/l.  179 
Post-operative ammonia was measured in 119 dogs with a median of 82μmol/l (range 13-180 
677). Paired pre and post-operative ammonia samples were available for 104 dogs 181 
(41.1%). There was a statistically significant decrease in ammonia after surgery from a 182 
median of 147.5μmol/l (range 8-544) to a median of 80.0μmol/l (range 13-677) 183 
(p<0.001). 184 
 185 
Twelve dogs (4.74%) did not survive to discharge, seven of these dogs died or were 186 
euthanized for reasons not related to PANS. Three dogs died or were euthanized due to 187 
severe gastrointestinal haemorrhage, one dog due to suspected portal hypertension and 188 
pulmonary thromboembolism,  one dog due to severe anaemia secondary to a 189 
coagulopathy, one dog due to a portal vein thrombus and one dog due to postoperative 190 
intussusception. 191 
 192 
Twenty-eight dogs (11.1%) developed PANS (Table 5) with the remaining 225 dogs 193 
(88.9%) not displaying any post-operative neurological complications. PANS score was 194 
mild (grade 1) in eleven dogs (39.3%), moderate (grade 2) in four dogs (14.3%) and 195 
severe (grade 3) in thirteen dogs (46.4%). Twelve dogs (42.9%) suffered post-operative 196 
generalized seizures (Table 4). Of the 28 dogs that suffered PANS, five (17.9%) did not 197 
survive to hospital discharge (Table 4). These dogs all suffered seizures meaning that 198 
5/12 dogs (41.7%) that suffered seizures post-operatively died or were euthanized. None 199 
of the five dogs that died due to seizures received peri-operative levetiracetam, four out 200 
of the seven dogs that had seizures but survived to discharge did receive pre-operative 201 
leviteracetam.  202 
 203 
Plasma osmolality was calculated at three time points. The median time interval from 204 
surgery to first sampling was 1 hour (range 0-4), from surgery to second sample was 8 205 
hours (range 5-14) and from surgery to third sample was 24 hours (range 14-32). 206 
Osmolality was calculated at first sampling in 143 dogs with a median of 284.6 (269.6-207 
316.0). Osmolality was calculated at second sampling in 131 dogs with a median of 282.7 208 
(263.4-317.0). Osmolality was calculated at third sampling in 131 dogs with a median of 209 
279.8 (265.5-325.4).  210 
 211 
Univariable analysis 212 
 213 
The results of the univariable binary logistic regression for possible risk factors of PANS 214 
and seizures are presented in Tables 5 and 6. 215 
 216 
Multivariable analysis 217 
 218 
The final model of risk factors for PANS included increasing age (p<0.001, Wald 16.561, 219 
odds ratio [Exp(B)] 1.476, confidence interval 1.223-1.780) and the presence of signs of 220 
HE immediately pre-operatively (p=0.038, Wald 4.305 odds ratio [Exp(B)] 2.704, 221 
confidence interval 1.057-6.922).   222 
 223 
The final model of risk factors for seizures included increasing age (p=0.009, Wald 224 
6.904, odds ratio [Exp(B)] 1.364, confidence interval 1.082-1.720) and the presence of 225 
signs of HE immediately pre-operatively (p=0.048, Wald 3.919 odds ratio [Exp(B)] 226 
3.538, confidence interval 1.013-12.363).   227 
 228 
Increasing age was significantly positively correlated with Osmolality 1 (p<0.001, 229 
R=0.349), Osmolality 2 (p<0.001, R=0.387), Osmolality 3 (p<0.001, R=0.563) and 230 
duration of clinical signs (p<0.001, R=0.401) and significantly negatively correlated with 231 
post-operative ammonia (p=0.005, R=0.255). Duration of clinical signs was significantly 232 
positively correlated with the duration of medical management (p<0.001, R=0.311). 233 
  234 
Discussion  235 
Although PANS do not occur frequently (11.1% in this study) they are a major cause of 236 
mortality in dogs that have undergone surgical CPSS attenuation. The unknown aetiology 237 
prevents aimed treatment and symptomatic treatment is centred on the use of anti-seizure 238 
medication to control neurological signs. Severe PANS may be refractory to such 239 
measures and this is reflected in a high mortality rate of 20-100%. 2,5–7,24,32,33  240 
 241 
PANS may develop due to the triggering of a change in the CNS environment following 242 
anaesthesia and surgery that has been “set up” by the prior exposure of the astrocytes to 243 
one or more substances implicated in the pathogenesis of HE.6,9 To our knowledge there 244 
has not been identification of a risk factor that is predictive for PANS or seizure activity 245 
following surgical attenuation of a single CPSS. Our aim was to ascertain if clinical, 246 
biochemical or patient specific risk factors for PANS could be identified. 247 
 248 
In this study the presence of HE immediately pre-operatively and age were independent 249 
risk factors for the development of PANS following surgical attenuation of a single 250 
CPSS. The odds of PANS occurring in dogs is increased 1.476 times with each year of 251 
age. The odds of PANS occurring in dogs with signs of HE immediately pre-surgery was 252 
2.704 times that of those without. 253 
 254 
Dogs that are older at the time of surgery have had longer exposure to alterations within 255 
the CNS. This fits with the suggestion that chronic and/or irreversible astrocyte damage 256 
by one or more neurotoxic substances is a trigger for the development of neurological 257 
abnormalities when the dog is challenged by an anaesthetic and surgical procedure. This 258 
is consistent with previous findings suggesting that older dogs are at an increased risk of 259 
post-operative complications, neurological or otherwise.2,6,7,9,23,34 A previous study 260 
suggested that age at diagnosis was not associated with long term survival and the authors 261 
concluded that there was no indication that surgical intervention should be performed 262 
early in life to be beneficial.35 However, the results of the current study would suggest 263 
that delaying surgery could increase the risk of PANS. 264 
 265 
Dogs that had signs of HE immediately prior to surgery either responded poorly to 266 
medical therapy or had not received medical therapy. CNS alterations may have been 267 
more severe, or the lack of medical therapy contributed to an unstable neurological state, 268 
resulting in a larger relative change in the CNS environment following shunt attenuation. 269 
The findings of the current study support the notion that alterations in the CNS pre-270 
operatively are implicated in the neurological dysfunction seen post attenuation. This is 271 
in agreement with a previous study which indicated that dogs without pre-operative HE 272 
have fewer complications after CPSS attenuation, compared with dogs with pre-operative 273 
HE.36 However, they are contrary to the results of another study which concluded that the 274 
presence of HE pre-operatively did not affect the likelihood of the development of PANS 275 
or seizure activity.2 Other studies have not been able to draw any conclusions as to the 276 
significance of pre-operative HE in the development of PANS.3,9 The reasons for 277 
discrepancies between studies are likely to include sample size, the retrospective nature 278 
of the studies and the lack of clarification of timing of observation of HE. The 279 
improvement of HE with medical management makes this information critical.  The 280 
separation of the clinical signs of pre-operative HE and post-operative PANS can be 281 
difficult, particularly in dogs that have undergone partial shunt attenuation. In this study, 282 
of the twenty eight dogs with PANS, nine dogs showed clinical signs of HE immediately 283 
pre-operatively. Paired (pre and post-operative) ammonia samples in three of the dogs 284 
affected by PANS showed a marked reduction in ammonia, lending evidence to two 285 
distinct neurological syndromes, and not simply a continuation of HE. 286 
 287 
Hyperammonaemia is a common finding in dogs with HE, yet dogs that have undergone 288 
CPSS attenuation show a decrease in serum ammonia and this has been observed in dogs 289 
with PANS.13,24,33 The conversion of ammonia to glutamine within the astrocyte is 290 
considered to be a factor in HE, resulting in osmotic stress and energy depletion.16,37 291 
However the severity of neurological signs does not always correlate with 292 
hyperammonaemia and serum levels of ammonia can be normal in dogs, cats and humans 293 
with HE, suggesting other pathways are also involved. 13,38,39 Pre-operative ammonia 294 
levels were not associated with the development of PANS in this study, suggesting that 295 
the pathogenesis of PANS is complex and not related to a sole neurotoxin. 296 
 297 
Interestingly, there were several risk factors evaluated in this study that were not found to 298 
be predictive of PANS. Peri-operative treatment with levetiracetam was instigated at our 299 
institution in 2012 as result of work by Fryer et al 3 suggesting peri-operative medication 300 
with levetiracetam reduced the risk of developing seizures post-operatively. However in 301 
the current study peri-operative levetiracetam did not affect the development of PANS or 302 
seizure activity which is therefore inconsistent with the aforementioned paper that only 303 
included dogs that developed seizures. Whilst prophylactic levetiracetam did not reduce 304 
PANS or seizures in this study, it did seem to be associated with reduced mortality in 305 
severely affected cases. However the cases receiving prophylactic levetiracetam were 306 
recent and therefore reduced mortality could be explained by increased experience 307 
treating PANS. It is also important to recognize that although cases receiving 308 
levetiracetam were treated for at least 24 hours pre-operatively and five days post-309 
operatively, there may have been variation in the dose and duration of treatment. These 310 
differences highlight the need for a prospective, controlled study to interrogate the role of 311 
peri-operative anti-seizure medication for the prevention of PANS.  312 
 313 
Neither extrahepatic or intrahepatic shunts were found to be at an increased risk of 314 
developing PANS or seizure activity in this study. Previously, one study found that dogs 315 
with extrahepatic shunts were significantly more likely to develop PANS and seizure 316 
activity compared to intrahepatic shunts.2 Additionally, the degree of attenuation 317 
achieved was not predictive of neurological dysfunction in the current study.  318 
 319 
In the univariable analysis age, the duration of the clinical signs, duration of medical 320 
management and osmolality at time points 2 and 3 were all significant, but of these, only 321 
age proved to be a risk factor in the multivariable model. The duration of clinical signs is 322 
closely related to age and these were significantly correlated. There was also a significant 323 
correlation between the duration of clinical signs and the duration of medical 324 
management, which is not surprising. The presence of HE pre-operatively was not 325 
significant in the univariable analysis but was a risk factor for PANS in the final model.  326 
 327 
There were also significant correlations between osmolality and age. Osmolality, 328 
specifically sodium, has been implicated in the pathogenesis of HE in human medicine 329 
16,29,40 and imbalance is likely to be implicated in HE in dogs, contributing to the 330 
alzheimer type II changes seen with astrocyte swelling. Interestingly, central pontine 331 
myelinolysis is associated with rapid correction of hyponatraemia,28 and therefore 332 
increased osmolality. In the current study osmolality was greater in dogs affected by 333 
PANS and seizures. The significant differences in osmolality between dogs with and 334 
without PANS is an interesting finding and worthy of further study. It is possible that the 335 
changes in post-operative osmolality are directly related to the occurrence of PANS, it is 336 
also possible that they are result of PANS. Additionally, it is possible that osmolality is 337 
related to age.  338 
 339 
The retrospective nature of this study is limiting, with smaller sub groups for several 340 
important variables, particularly osmolality. Although analysis of complications and 341 
behavioural changes used a detailed grading scale, retrospective analysis of these records 342 
is open to interpretation. Furthermore, information has been collected over an extended 343 
period. While this allows a large dataset to be analysed it also introduces variability in the 344 
surgical, anaesthetic and medical management. 345 
 346 
Age and the presence of HE immediately pre-operatively were identified as risk factors 347 
for PANS and seizures in this study, suggesting surgery should not be delayed for a 348 
prolonged period and emphasizing the need to stabilise clinical signs of HE before 349 
surgery. Further work is necessary to elucidate the underlying mechanism of PANS so 350 
that strategies can be targeted to prevent or more effectively treat PANS. Although it will 351 
be difficult to enroll sufficient dogs in a timely manner, a randomised, prospective study 352 
would be invaluable to confirm if there is any potential benefit of prophylactic anti-353 
seizure medications in dogs undergoing surgery for a CPSS.  354 
  355 
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  472 
Tables 473 
Table 1: Grading system for hepatic encephalopathy (HE) prior to medical therapy in 474 
dogs, adapted from Proot et al 41 475 
HE Grade Clinical signs 
1 Normal, absence of abnormal clinical signs 
2 Lethargy, apathy, minimal disorientation, subtle personality change, 
inappropriate behavior 
3 Hypersalivation, severe ataxia, somnolence but responds to verbal stimuli, 
circling, head pressing 
4 Coma, stupor, repeated seizures.  
 476 
  477 
Table 2: Grading system for clinical response to pre-operative medical management of 478 
hepatic encephalopathy (HE) in dogs with a single congenital portosystemic 479 
shunt(CPSS)30 480 
 481 
Grade Clinical signs 
Good No remaining clinical signs 
Moderate Some improvement but clinical signs of HE still present 
Poor Little or no clinical improvement 
 482 
  483 
Table 3: Grading system for Post Attenuation Neurological Signs (PANS) in dogs 484 
undergoing surgical management of a single congenital portosystemic shunt (CPSS) 485 
 486 
Grade Clinical signs 
1: Mild Subtle depression or behavior change, mild tremors or twitching. Self 
resolves or responds immediately to anti-epileptic drug (AED) 
administration. 
2: Moderate Marked depression or behavior change, whole body tremors or twitching, 
+/- reduced response to visual stimuli. Requires one or more intravenous 
AED and ongoing increases in drugs with regular monitoring/ICU support 
to control PANS. 
3: Severe Progressive, severe depression/coma, nystagmus, complete blindness, 
seizures, requires maximum intervention with two or more AED +/- 
propofol and/or other drugs with continuous monitoring/ICU support. 
 487 
  488 
Table 4: Details and outcome for 28 dogs affected by Post Attenuation Neurological 489 
Signs (PANS) following surgical treatment of a single congenital portosystemic shunt 490 
(CPSS) 491 
 492 
 493 
Case PANS 
grade 
Nature of PANS Pre op 
levetirac
etam 
Survival 
to 
discharge 
1 1 Mild neurological signs for first few hours, resolved without 
treatment. 
No Yes 
2 1 Inappropriate mentation 36 hours post surgery responded 
well to phenobarbitone and diazepam. 
No Yes 
3 1 Prolonged recovery and ataxia, resolved with no treatment. Yes Yes 
4 1 Mild tremor 36 hours post surgery quickly responsive to 
phenobarbitone. 
No Yes 
5 1 Tremors and ataxia immediately post surgery, resolved with 
potassium bromide and levetiracetam. 
No Yes 
6 1 Mild tremors 27 hours post surgery, resolved with no further 
treatment added to preoperative levetiracetam. 
Yes Yes 
7 1 Mild tremors 96 hours post surgery, resolved with addition 
of phenobarbitone to preoperative levetiracetam. 
Yes Yes 
8 1 Paddling forelimbs on recovery, resolved with midazolam. No Yes 
9 1 Mild tremor resolved with no treatment. No Yes 
10 1 Mild tremor 40 hours post surgery, resolved with addition of 
phenobarbitone to preoperative levetiracetam. 
Yes Yes 
11 1 Tremors 24 hours post surgery, resolved with no treatment. No Yes 
12 2 Depression, circling and ataxia, 48 hours post surgery 
resolved with phenobarbitone. 
No Yes 
13 2 Depression, central blindness, head pressing 86 hours post 
surgery, gradual response to phenobarbitone. 
No Yes 
14 2 Depression, visual and proprioceptive deficits 86 hours post 
surgery good response to phenobarbitone. 
No Yes 
15 2 Depression, circling, central blindness 84 hours post surgery 
successful treatment with phenobarbitone. 
No Yes 
16 3 Seizures12 hours post surgery, responded to phenobarbitone. No Yes 
17 3 Seizures 12 hours post surgery good response to 
phenobarbitone, potassium bromide and diazepam. 
No Yes 
18 3 Seizures at 72 hours post surgery. Successfully treated with 
phenobarbitone, levetiracetam and propofol CRI. 
No Yes 
19 3 Seizures activity 6 hours post surgery, improved with 
phenobarbitone. 
No Yes 
20 3 Circling, ataxia, visual deficits and seizure activity 78 hours 
post surgery resolved with addition of phenobarbitone to 
preoperative levetiracetam. 
Yes Yes 
21 3 Seizures 28 hours post surgery, resolved with addition of 
phenobarbitone to preoperative levetiracetam. 
Yes Yes 
22 3 Tremors, ataxia and seizures at 52 hours post surgery, 
resolved with the addition of phenobarbitone to preoperative 
levetiracetam. 
Yes Yes 
23 3 Depression, ataxia and central blindness 90 hours post 
surgery, responded to phenobarbitone but still blind at 
discharge. 
Yes Yes 
24 3 Seizures 24 hours post surgery, treated with phenobarbitone 
and propofol continuous rate infusion (CRI). 
No Euthanize
d 
25 3 Seizures 48 hours post surgery, no response to 
phenobarbitone, propofol CRI controlled seizures but unable 
to wean off infusion. 
No Euthanize
d 
26 3 Seizures 48 hours post surgery no response to 
phenobarbitone and diazepam. Propofol CRI controlled 
seizures but unable to wean off infusion. 
No Euthanize
d 
27 3 Seizures 12 hours post surgery, refractory to phenobarbitone 
and propofol CRI. 
No Euthanize
d 
28 3 Seizures 40 hours post surgery, refractory to phenobarbitone 
and levetiracetam. Responded to propofol CRI but developed 
aspiration pneumonia. 
No Euthanize
d 
 494 
  495 
Table 5: Comparison of clinical variables for dogs with a single congenital 496 
portosystemic shunt (CPSS) that suffered post attenuation neurological signs (PANS) 497 
following surgical treatment and those that did not 498 
 499 
Variable No PANS – 225 dogs PANS – 28 dogs P value 
Type of shunt Extrahepatic 173 (76.9%) 
Intrahepatic 52 (23.1%) 
Extrahepatic 23 (82.1%) 
Intrahepatic 5 (17.9%) 
0.532 
Degree of attenuation Complete 90 (40.0%) 
Partial 135 (60.0%) 
Complete 15(53.6%) 
Partial 13 (46.4%) 
0.173 
Pre-operative albumin g/l 26.2 (7.9-35.5) 
202 dogs 
26.2 (22.0-35.8) 
25 dogs 
0.154 
Pre-operative ammonia 
μmol/l 
160 (range 8-544)  
163 dogs 
176 (range 36-590) 
23 dogs 
0.434 
Post-operative ammonia 
μmol/l 
86 (range 13-677) 
105 dogs 
56 (range 14-142) 
14 dogs 
0.061 
Age in years 0.79 (0.20-7.80) 
225 dogs 
2.58 (range 0.33-11.98) 
28 dogs 
<0.001 
Hepatic encephalopathy 
(HE) present prior to 
medical management 
No 65 (28.9%) 
Yes 160 (71.1%) 
No 6 (21.4%) 
Yes 22 (78.6%) 
0.410 
Duration of clinical signs 
pre-surgery in days 
56 days (8-1436) 
225 dogs 
103 days (5-1269) 
28 dogs 
0.020 
Duration of medical 
management pre-surgery 
in days 
23 days (range 0-290) 
225 dogs 
21 days (range 0-730) 
28 dogs 
0.037 
Response to medical 
management 
Good 159 (75.4%) 
Moderate / poor 52 
(24.6%) 
Good 17 (63.0%) 
Moderate / poor 10 
(37.0%) 
0.172 
Signs of HE immediately 
pre-operatively 
No 186 (82.7%) 
Yes 39 (17.3%) 
No 19 (67.9%) 
Yes 9 (32.1%) 
0.065 
Prophylactic anti-seizure 
medication 
Yes 48 (21.3%) 
No 177 (78.7%) 
Yes 6 (21.4%) 
No 22 (78.6%) 
0.991 
Osmolality at post-
operative time point 1 
284.5 (269.6-310.4) 
129 dogs 
286.0 (274.2-316.0) 
14 dogs 
0.067 
Osmolality at post-
operative time point 2 
282.4 (263.4-310.4) 
117 dogs 
291.2 (269.1-317.0) 
14 dogs 
0.016 
Osmolality at post-
operative time point 3 
279.8 (265.5-305.5) 
121 dogs 
285.2 (271.7-325.4) 
10 dogs 
0.020 
  500 
Table 6: Comparison of clinical variables for dogs with a single congenital portosystemic 
shunt(CPSS) that suffered seizures following surgical treatment and those that did not. 
Variable No seizures – 241 dogs Seizures – 12 dogs P value 
Type of shunt Extrahepatic 186 (77.2%) 
Intrahepatic 55 (22.8%) 
Extrahepatic 10 (83.3%) 
Intrahepatic 2 (16.7%) 
0.620 
Degree of attenuation Complete 98 (40.7%) 
Partial 143 (59.3%) 
Complete 7 (58.3%) 
Partial 5 (41.7%) 
0.234 
Pre-operative albumin g/l  26.2 (range 7.9-35.8) 
 216 dogs 
 26.2 (range 23.0-31.5) 
11 dogs 
0.450 
Pre-operative ammonia 
μmol/l 
 160.5 (range 8.0-562.0)  
 174 dogs 
 172.0 (range 36.0-590.0) 
12 dogs 
0.816 
Post-operative ammonia 
μmol/l 
85.0 (range 13.0-677.0) 
113 dogs 
52.7 (range 28.0-106.0) 
6 dogs 
0.156 
Age in years 0.8 (range 0.2-12.0) 
 241 dogs 
 2.8 (range 0.8-8.5) 
 12 dogs 
0.006 
Hepatic encepalopathy 
(HE) present prior to 
medical management 
No 68 (28.2%) 
Yes 173 (71.8%) 
No 3 (25.0%) 
Yes 9 (75.0%) 
0.809 
Duration of clinical signs 
presurgery in days 
 55 days (range 5-1436) 
 241 dogs 
195.5 days (range 54-
385) 
12 dogs 
0.162 
Duration of medical 
management pre-surgery 
in days 
24 days (range 4-730) 
226 dogs 
25 days (range 6-181) 
12 dogs 
0.689 
Response to medical 
management 
Good 169 (74.8%) 
Moderate / poor 57 
(25.2%) 
Good 7 (58.3%) 
Moderate / poor 5 
(41.7%) 
0.215 
Signs of HE immediately 
pre-operatively 
No 198 (82.2%) 
Yes 43 (17.8%) 
No 7 (58.3%) 
Yes 5 (41.7%) 
0.051 
Prophylactic anti-seizure 
medication 
Yes 51 (21.2%) 
No 190 (78.9%) 
Yes 3 (25.0%) 
No 9 (75.0%) 
0.752 
Osmolality at post-
operative time point 1 
284.5 (range 269.6-
310.4) 
138 dogs 
295.1 (283.4-316.0) 
5 dogs 
0.001 
Osmolality at post-
operative time point 2 
282.3 (range 263.4-
310.4) 
126 dogs 
298.0 (range 294.1-
317.0) 
5 dogs 
0.002 
Osmolality at post-
operative time point 3 
279.8 (range 265.5-
305.5) 
127 dogs 
293.7 (range 285.1-
325.4) 
4 dogs 
0.006 
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